Gastrointestinal Cancer | Norton Healthcare

Indication: Gastrointestinal Cancer

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

Pancreatic

Sub-indication: Pancreatic Cancer

Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: FibroGen, Inc

Learn more at ClinicalTrials.gov

Email for more information: GI-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.